Results from a prespecified interim analysis of the KEYNOTE-564 trial—which investigated adjuvant pembrolizumab vs placebo following nephrectomy in patients with clear cell renal cell carcinoma—were presented at the 2024 ASCO Genitourinary Cancers Symposium (Abstract LBA359).
